The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities
- 1 February 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Nuclear Medicine Communications
- Vol. 32 (2), 85-90
- https://doi.org/10.1097/mnm.0b013e328341c898
Abstract
Objective To evaluate the clinical impact of fluorodeoxyglucose (FDG)-PET/computed tomography (CT) scan on restaging breast cancer patients with rising tumor markers and negative or equivocal findings in conventional imaging studies. Methods We studied 46 patients with breast cancer of an average age of 57.6 years (ranging from 38 to 68 years). All patients were referred for an FDG-PET/CT scan because of elevated tumor markers, without any other obvious clinical or laboratory sign of relapse. Conventional imaging study results were either negative (29 out of 46 patients) or inconclusive (17 out of 46 patients). All patients underwent a whole-body FDG-PET/CT scan in a combined PET/CT. The findings were confirmed by a follow-up at least 9 months later, and when it was possible, final diagnosis was obtained by histopathology. Results In 34 out of 46 patients, an FDG-PET/CT scan showed sites of increased metabolic activity, indicating active disease. In 23 out of 46 patients, the therapeutic approach and further clinical management were affected. The FDG-PET/CT scan was true-positive in 33 patients, false-positive in one patient, false-negative in five patients, and true-negative in seven patients. On the basis of our results in this population, an FDG-PET/CT scan had a sensitivity of 86.8%, a specificity of 87.5%, and an accuracy of 86.9%. The positive predictive value was 97.1% and the negative predictive value was 58.3%. Clinical management was affected in 50% of these patients. Conclusion The FDG-PET/CT scan plays an important role in restaging breast cancer patients with rising tumor markers and negative or equivocal findings in conventional imaging techniques, with a consequent significant clinical impact on further management in these patients.Keywords
This publication has 13 references indexed in Scilit:
- Integration of Imaging in the Management of Breast CancerJournal of Clinical Oncology, 2005
- A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastasesBreast Cancer Research and Treatment, 2005
- Ca 15-3 in the follow-up of localised breast cancer: a prospective studyEuropean Journal of Cancer, 2002
- Staging of Breast Cancer: New Recommended Standard ProcedureBreast Cancer Research and Treatment, 2002
- Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized TrialsJournal of Clinical Oncology, 2001
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 TrialJNCI Journal of the National Cancer Institute, 2000
- The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast CancerClinical Positron Imaging, 2000
- Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.American Journal of Roentgenology, 1998
- Routine follow up of breast cancer in primary care: randomised trialBMJ, 1996